Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer. Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 51 points (-0.3%) at 18,140 as of Monday, May 11, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,286 issues advancing vs. 1,726 declining with 119 unchanged. The Drugs industry currently sits up 0.6% versus the S&P 500, which is down 0.2%. Top gainers within the industry include Bristol-Myers Squibb Company ( BMY), up 1.4%, Teva Pharmaceutical Industries ( TEVA), up 1.1%, GlaxoSmithKline ( GSK), up 1.3%, Eli Lilly and ( LLY), up 0.7% and AstraZeneca ( AZN), up 0.5%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. AbbVie ( ABBV) is one of the companies pushing the Drugs industry higher today. As of noon trading, AbbVie is up $0.41 (0.6%) to $65.65 on light volume. Thus far, 3.3 million shares of AbbVie exchanged hands as compared to its average daily volume of 12.4 million shares. The stock has ranged in price between $65.08-$65.80 after having opened the day at $65.19 as compared to the previous trading day's close of $65.24. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. AbbVie has a market cap of $103.0 billion and is part of the health care sector. Shares are down 1.1% year-to-date as of the close of trading on Friday. Currently there are 8 analysts who rate AbbVie a buy, no analysts rate it a sell, and 2 rate it a hold. TheStreet Ratings rates AbbVie as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and solid stock price performance. However, as a counter to these strengths, we find that net income has been generally deteriorating over time. Get the full AbbVie Ratings Report now. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.